Johnson & Johnson (NYSE:JNJ) Trading Down 1.1%

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price fell 1.1% during trading on Thursday . The stock traded as low as $151.70 and last traded at $151.81. 1,428,737 shares were traded during trading, a decline of 80% from the average session volume of 7,293,876 shares. The stock had previously closed at $153.50.

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Bank of America dropped their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating and lifted their target price for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, May 6th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $175.86.

Johnson & Johnson Stock Down 2.5 %

The company has a market capitalization of $360.28 billion, a price-to-earnings ratio of 9.33, a PEG ratio of 2.51 and a beta of 0.55. The stock's fifty day simple moving average is $151.53 and its two-hundred day simple moving average is $155.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the prior year, the firm posted $2.68 EPS. Johnson & Johnson's revenue was up 2.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.31%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson's dividend payout ratio (DPR) is presently 30.92%.

Institutional Trading of Johnson & Johnson

Hedge funds have recently made changes to their positions in the stock. Dock Street Asset Management Inc. raised its position in shares of Johnson & Johnson by 25.9% in the third quarter. Dock Street Asset Management Inc. now owns 3,276 shares of the company's stock valued at $510,000 after purchasing an additional 674 shares during the period. Perfromance Wealth Partners LLC increased its position in Johnson & Johnson by 1.3% during the third quarter. Perfromance Wealth Partners LLC now owns 53,086 shares of the company's stock worth $8,268,000 after acquiring an additional 660 shares during the period. SC&H Financial Advisors Inc. increased its position in Johnson & Johnson by 5.1% during the third quarter. SC&H Financial Advisors Inc. now owns 2,149 shares of the company's stock worth $335,000 after acquiring an additional 105 shares during the period. Choate Investment Advisors increased its position in Johnson & Johnson by 13.6% during the third quarter. Choate Investment Advisors now owns 90,366 shares of the company's stock worth $14,075,000 after acquiring an additional 10,822 shares during the period. Finally, Strengthening Families & Communities LLC increased its position in Johnson & Johnson by 6.9% during the third quarter. Strengthening Families & Communities LLC now owns 15,243 shares of the company's stock worth $2,374,000 after acquiring an additional 981 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.